[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ohio State University Comprehensive Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":558},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,78,0,25,[9,44,72,95,117,138,165,187,206,229,249,268,293,316,335,354,376,395,415,443,460,478,496,514,537],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053408",false,"NCT07699991","A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors","Implementation of a Navigation Program for Breast Cancer Survivors","Inclusion Criteria:\n\n* GENERAL INCLUSION (PRIMARY OBJECTIVE): Ages 18+\n* GENERAL INCLUSION (PRIMARY OBJECTIVE): Diagnosed with non-metastatic breast cancer\n* GENERAL INCLUSION (PRIMARY OBJECTIVE): Received care at Stefanie Spielman Breast Center\n* COACHING INCLUSION (SECONDARY OBJECTIVE): Referred patients who fall under any of the following:\n\n  * Black and\u002For Hispanic\n  * Ages ≥ 70\n  * Reside in a ZIP code classified as rural by United States Department of Agriculture (USDA) Rural-Urban Commuting Area (RUCA) codes\n\nExclusion Criteria:\n\n* Metastatic breast cancer at time of referral\n* Prisoners or individuals unable to consent\n* Non-English and non-Spanish speakers","FEMALE","18 Years",{"count":19,"type":20},330,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial studies whether a navigation program improves survivorship support service participation among survivors of breast cancer that has not spread from where it first started (primary site) to other places in the body (non-metastatic). Advances in treatment have caused the number of breast cancer survivors to grow. As this number increases, there are reported unmet supportive care needs in this population, including psychological distress and limitations in physical functioning. To address these needs, many cancer centers offer programming on a variety of topics including psychological services, exercise counseling, and nutrition counseling. Research has shown that while interest in these survivorship programs is high, participation remains low, especially among minority women. Navigation is a healthcare service that is designed to guide a patient through the healthcare system and reduce barriers to timely screening, follow-up, diagnosis, treatment, and supportive care. The navigation program in this trial is specifically focused on helping breast cancer survivors schedule and attend survivorship consultation appointments as well as providing additional support to underserved\u002Fvulnerable patients. A navigation program may be effective in improving survivorship support service participation among non-metastatic breast cancer survivors.",[26,27,28,29,30],"Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Localized Breast Carcinoma","NOT_YET_RECRUITING","2026-07-07",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":20},"2026-09-01",{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"Ohio State University Comprehensive Cancer Center","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100627366","NCT07447700","A Pilot Study to Evaluate the Effectiveness of Focused Massage on Pain, Mobility, and Quality of Life During Radiation Treatment for Patients With Breast Cancer","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Diagnosis of breast cancer\n3. Treatment plan for curative intent radiation at SSBC\n4. Radiation treatment frequency can be daily, every other day, and twice weekly\n5. Agreeable to and available for focused chair massages post-radiation treatments during the prescribed treatment period\n\nExclusion Criteria:\n\n1. Patients with recurrent disease (breast cancer)\n2. Patients treated palliatively with radiation treatments\n3. Inability to read and\u002For understand English (consent and questionnaires in English)\n4. Patients with documented cognitive disorder that limits the ability to independently read, understand, and\u002For complete the survey measures; i.e. dementia, Alzheimer's\n5. Patients with major psychiatric disorders not controlled by medication or other psychiatric treatments","ALL",{"count":51,"type":20},55,[23],"The goal of this interventional study is to to evaluate the effectiveness and acceptability of a focused upper body massage when offered after radiation treatments to participants diagnosed with breast cancer. Given the prevalence of musculoskeletal complaints during radiation therapy delivery and acknowledging the emotional stress associated with breast cancer diagnosis and treatment, the aims of this pilot study are to: 1) evaluate the effectiveness of a focused upper body massage, available after radiation treatments, on patient's muscle and joint achiness and disability\u002Fsymptoms of the upper extremities; 2) evaluate the effectiveness of a focused chair massage, available after radiation treatments on health-related quality of life; 3) assess the need for repeating the pre-radiation simulation process and revising the established treatment plan; and 4) and evaluate patient acceptability of the massages offered during the course of radiation treatment.",[55,56],"Breast Cancer","Radiation Therapy Patient",[58,59,60,61,62],"breast cancer","radiation therapy","muscle and joint achiness","quality of life","re-simulation","RECRUITING","2026-06-30",{"date":66,"type":35},"2026-07-02",{"date":68,"type":35},"2026-04-01",{"date":70,"type":20},"2027-08-30",{"name":41,"class":42},{"id":73,"slug":4,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":49,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":94,"locationsCount":43},"100573038","NCT06741072","BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants","A Phase 1B Double Blinded Randomized Trial Evaluating Safety, Tolerability, and Immune Response of OSU-2131 a BZLF1 Peptide Vaccine With Stimulon™ QS-21 Solution Adjuvant in Healthy Volunteers and Patients Awaiting Solid Organ Transplantation","Inclusion Criteria:\n\n* Healthy volunteers and patients awaiting solid organ transplantation (SOT) must have at least one allele for HLA-B\\*08:01\n* Subjects can be Epstein-Barr virus (EBV) seronegative or seropositive\n* Subjects must be seronegative for HIV\n* Subjects must be seronegative for hepatitis B and C\n* Have baseline chemistry and hematology (hemoglobin, white blood cells, absolute neutrophil count, eosinophils) within normal limits\n* Prothrombin time (PT) and partial thromboplastin time (PTT) below the upper limit of normal\n* Platelets above the lower limit of normal (LLN)\n* Basophils, lymphocytes, and monocytes must be within 1.2 x upper limit of normal (ULN) or 0.8 x LLN and considered not clinically significant by the investigator\n* Total creatine kinase (CK) laboratory values \\\u003C 1.25 x the upper limit of normal (according to the normal reference ranges of the Ohio State University \\[OSU\\] laboratory) at baseline (screening \\& pre-study visit) and considered not clinically significant by the investigator\n* Subjects must not be taking antiviral therapy\n* Must be ≥ 18 years of age and ≤ 65 years of age and willing to either use an effective method of contraception or abstain from sexual activity for at least 3 months following the last dose of vaccination\n* Female of childbearing potential must have a negative serum pregnancy test prior to the first study drug\u002Fplacebo (PBS) administration\n* Agree not to receive any other investigational drug while enrolled in this study\n* Provide written informed consent according to International Conference on Harmonization-Good Clinical Practice (ICH-GCP) and local regulations\n* Following successful completion of safety evaluation for the phase 1 dose escalation phase of this trial in healthy volunteers and review of this data by the Sponsor and Food and Drug Administration (FDA), we plan to enroll a second cohort of patients awaiting solid organ transplantation (SOT). We will recruit patients with end stage renal disease (ESRD) who are awaiting kidney transplantation. ESRD is defined according to 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease (Acosta-Ochoa et al, J Clin Med, 8(9):1323, 2019). KDIGO defines ESRD as: stage 4: severe reduction in glomerular filtration rate (GFR) (15 to 29 mL\u002Fmin); stage 5: renal failure (GFR less than 15 mL\u002Fmin). Patients will qualify for ESRD \u002F kidney transplantation per need for maintenance dialysis due to one or more of the criteria related to renal insufficiency: volume overload, metabolic acidosis, electrolyte disturbance, drug toxicity, etc. Patients will be regularly undergoing hemodialysis or peritoneal dialysis for metabolic support. Patients will be excluded from the study if they have any unstable medical conditions which the investigator believes would preclude participation in the study. These conditions include but are not limited to cardiorenal and hepatorenal syndromes\n\nExclusion Criteria:\n\n* Severe active infection, compromised cardiopulmonary function, or other serious medical illness that, in the opinion of the principal investigator, would prevent study completion\n* History of chronic active EBV infection, active infectious mononucleosis (or infectious mononucleosis within 6 months of enrollment), or other EBV-related disorder as determined by principal investigator (PI)\n* History of immune suppression or autoimmune disorder\n* Concomitant use of systemic corticosteroids or other immunosuppressive medications (including nasal and inhaled steroids). The use of nasal steroids for seasonal rhinitis is acceptable\n* Pregnant or breastfeeding subjects\n* For patient enrollment on the second cohort, \"patients awaiting SOT\", we will consider patients awaiting kidney transplantation who are receiving maintenance renal replacement therapy (dialysis). Most patients on routine renal replacement therapy (dialysis) will present with stable chemistry, acid base balance, volume status and clear mental status. For patients who are non-compliant with routine dialysis, laboratory abnormalities and acid base, volume status can become abnormal. Specific dose limiting toxicity (DLT) criteria that may relate to patients with ESRD include laboratory parameters that may altered due to missed dialysis session(s). Most laboratory abnormalities in such patients can be corrected by restarting dialysis or blood transfusions. Outside these specific variables, we do not expect to see specific DLT criteria for patients with ESRD on this study. Metabolic derangement such as acid base imbalance, hyperkalemia and volume overload as a result of missing dialysis session. Study stopping rule for subjects awaiting organ transplant: Occurrence of this event in two or more subjects should result in study pause. Patients who are unable to adhere to routine dialysis will be excluded from the study if they have any unstable medical conditions which the investigator believes would preclude participation in the study. These conditions include but are not limited to cardiorenal and hepatorenal syndromes",true,"65 Years",{"count":51,"type":20},[82],"PHASE1","This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and related cancers in healthy volunteers and patients awaiting a solid organ transplant. Currently, patients who receive an organ transplant receive immune suppression therapy which can make it harder for the body to fight infections. This treatment also increases the risk for cancers that are triggered by the EBV. Vaccines made from synthetic peptide (RAKFKQLL) derived from the BZLF1 protein, may help the body build an effective immune response against EBV infections. QS-21, a saponin adjuvant, is a substance from plants that, when given with vaccine therapy, may improve the way the immune system responds to disease. Giving OSU-2131 with QS-21 may help the immune system fight EBV and protect against EBV infection and the cancers that it can cause in patients awaiting solid organ transplants.",[85,86,87,88,89],"Chronic Kidney Disease, Stage 4","Chronic Kidney Disease, Stage 5","EBV-Related Lymphoproliferative Disorder","EBV-Related Malignant Neoplasm","Post-Transplant Lymphoproliferative Disorder",{"date":66,"type":35},{"date":92,"type":35},"2026-06-28",{"date":39,"type":20},{"name":41,"class":42},{"id":96,"slug":4,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100252131","NCT02560883","Hairy Cell Leukemia Patient Data Registry","Clinical Research in Hairy Cell Leukemia: Surveillance and Documentation of Clinical Outcomes in a Rare Form of Adult Leukemia","HCL-PDR","Inclusion:\n\n* Patients with classic hairy cell leukemia\n* Patients with the variant of hairy cell leukemia.\n\nExclusion:\n\n* Children are excluded from the study, since Hairy Cell Leukemia wasn't described in children.",{"count":103,"type":20},5000,"OBSERVATIONAL","The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and\u002For mortality and improving the quality of life of patients diagnosed or living with hairy cell leukemia. With approximately 1,000 new cases of this rare disease identified in the US each year, HCL represents 2% of all cases of leukemia in adults. Considering the rarity of this chronic leukemia, the Hairy Cell Leukemia Foundation (HCLF), in partnership with investigators from its Centers of Excellence, seeks to develop a registry to help researchers identify new trends in outcomes, recognize the most effective treatments, discover previously unknown complications of the disease, and design clinical trials for new therapies.",[107],"Leukemia, Other",[109],"Hairy Cell",{"date":66,"type":35},{"date":112,"type":35},"2013-01-02",{"date":114,"type":20},"2030-12-31",{"name":41,"class":42},8,{"id":118,"slug":4,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":78,"sex":49,"minAge":124,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":43},"100574765","NCT06763536","Oral Nicotine Pouches Versus Nicotine Replacement Therapy to Reduce Cigarette Use for Smokers in Rural Appalachia","Testing Oral Nicotine Pouches to Reduce Smoking-Related Cancer in Rural Appalachia","ARISE","Inclusion Criteria:\n\n* Read and speak English\n* 21 years or older\n* Smoke ≥ 5 cigarettes per day for the past year\n* Willing to use Oral Nicotine Pouches (ONP) or Nicotine Replacement Therapy (NRT)\n* Live in a rural Appalachian County\n* Have a smartphone and\u002For willing to use a smartphone for study purposes (smartphones may be provided to participants for study purposes only)\n* Willing to blow air into a handheld study device\n* If capable of becoming pregnant, verbal confirmation of not being pregnant based on urine pregnancy test results\n\nExclusion Criteria:\n\n* Report currently using smoking cessation medications, NRT, or actively seeking treatment for smoking cessation\n* Use of ONPs in past 3 months\n* Use of Nicotine Replacement Therapies in past 3 months\n* Use of other tobacco products \\> 10 days\u002Fmonth\n* Unstable or significant medical condition\n* Unstable or significant psychiatric conditions (past and stable conditions will be allowed)\n* History of cardiac event or distress within the past 3 months\n* Live in same household as another study participant.\n* Currently pregnant, planning to become pregnant within 6 months, or breastfeeding","21 Years",{"count":126,"type":20},1000,[23],"This clinical trial compares the use of oral nicotine pouches to nicotine replacement therapy, consisting of nicotine patches and lozenges, to reduce cigarette use in smokers living in rural Appalachia. The lung and oral cancers that plague Appalachia are fueled by cigarette smoking. Oral nicotine pouches which contain nicotine but no tobacco leaf, present a new opportunity to reduce cancer risk among Appalachian adults who smoke. Oral nicotine pouches and nicotine replacement therapy may work well to reduce cigarette use for smokers in rural Appalachia.",[130],"Cigarette Smoking-Related Carcinoma","2026-06-26",{"date":64,"type":35},{"date":134,"type":35},"2025-06-13",{"date":136,"type":20},"2028-12-31",{"name":41,"class":42},{"id":139,"slug":4,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100449773","NCT05136846","Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer","A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) =\\\u003C grade 1 (except alopecia) at the time of enrollment\n* Absolute neutrophil count \\>=1.5 x 10\\^9\u002FL\n* Hemoglobin \\>= 9 g\u002FdL\n* Platelets \\>= 100 x 10\\^9\u002FL\n* Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN\n* Creatinine \\\u003C 1.5 mg\u002FdL or calculated creatinine clearance\\* \\>= 50 mL\u002Fmin or 24-hour urine creatinine clearance \\>= 50 mL\u002Fmin\n\n  * Calculated by the Cockcroft-Gault formula •\\>= 18 years old\n* Non-small cell lung cancer (NSCLC), histologically and\u002For cytologically proven\n* Clinical American Joint Committee on Cancer (AJCC) stage II-III NSCLC (T1-4N0-3M0) and select patients with stage IV oligometastatic disease.\n\n  * For patients with oligometastatic disease (up to 5 total sites of disease) for whom definitive CRT or RT to the primary and regional lymph nodes is recommended by the multidisciplinary team, each individual metastatic tumor would be considered an additional site of disease with the exception of brain metastases. Up to 10 brain metastases would be considered as 1 site.\n  * Patients with oligometastatic disease will be allowed to receive adjuvant systemic therapy at the discretion of the medical oncologist and additional local therapy to metastatic sites at the discretion of the multidisciplinary team\n* Patients must be considered unresectable or medically-inoperable if stage II-III NSCLC\n\n  * Patients with a local or regional recurrence following surgical resection for whom definitive CRT or RT to disease in the chest is recommended by the multidisciplinary team will be considered eligible\n* Patients must have fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)-computed tomography (CT) scan (or CT chest\u002Fabdomen\u002Fpelvis with IV contrast), and magnetic resonance imaging (MRI) brain with IV contrast (preferred) or CT scan of the brain with contrast. Non-contrast MRI scans of the chest\u002Fabdomen\u002Fpelvis or brain are permitted for workup if patient has allergy to CT contrast or renal insufficiency\n* Patients must have vital signs, history\u002Fphysical examination, laboratory studies (complete blood count \\[CBCP\\] with differential, chemistries including liver function tests, creatinine clearance (CrCl) assessment; pregnancy test if needed within 14 days of registration)\n* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* No history of complete atrioventricular block, hepatic dysfunction (e.g. cirrhosis), glaucoma, or priapism\n* Patients must be a minimum of 3 weeks from thoracotomy (if performed) and well-healed before starting treatment\n* Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Women of child-bearing potential (WOCBP) must have a negative pregnancy test within 14 days of registration. Urine human chorionic gonadotropin (HCG) is an acceptable pregnancy assessment\n* Nursing women may participate only if nursing is discontinued, due to the possibility of harm to nursing infants from the treatment regimen\n* Women\u002Fmen of reproductive potential must be counselled on contraception\u002F abstinence while receiving the study treatment\n\n  * Women of childbearing potential are required to use an effective method of contraception from the time of negative serum pregnancy test, throughout the study duration, and until 6 months after the last dose of radiation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n  * Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after completion of study drug administration\n* For patients planning to undergo CRT, patient is suitable to receive standard chemotherapy per treating medical oncologist with radiation during study treatment\n\nINCLUSION CRITERIA FOR MRI IMAGING SUB-STUDY:\n\n•Patients must consent to participate in the main part of this study and be enrolled into the expansion cohort, or consent to participate in the main part of this study and also consent to participate in the optional MRI Imaging study\n\nExclusion Criteria:\n\n* Patients with history of pneumonectomy\n* History of active connective tissue disease (scleroderma) or idiopathic pulmonary fibrosis\n* History of previous radiation therapy which would result in overlapping radiation fields\n* Subjects who are breast-feeding and plan to continue breast-feeding during therapy, or have a positive pregnancy test will be excluded from the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n* Hepatic insufficiency resulting in jaundice, or not meeting laboratory values above (albumin, total bilirubin, AST\u002FALT)\n* Patients enrolled into the expansion cohort must be able to complete the MRI Sub-study, or at a minimum attempt the first scan of the MRI Sub-study\n* Any serious and\u002For unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the treating physicians. This could include severe, active co-morbidities such as:\n\n  * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months\n  * Transmural myocardial infarction within the last 6 months\n  * Acquired immune deficiency syndrome (AIDS) based upon the current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive\n  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration\n* Patients who are presently receiving nitrates or nitroglycerin, or have received these medications within 30 days of day 1 of protocol treatment\n* Patients who are currently taking Sildenafil should agree to discontinue use for 2 days prior to initiation of papaverine, during the duration of study, and for 2 days after last dose of papaverine\n\nEXCLUSION CRITERIA FOR MRI IMAGING SUB-STUDY:\n\n* Any medical contraindication to MR imaging (e.g. pacemakers, metallic implants, aneurysm clips, pregnancy, nursing mothers, weight greater than 350 pounds)\n* Severe anxiety\u002Fclaustrophobia related to MR imaging despite medications to relieve anxiety\u002Fclaustrophobia\n* Patients who use supplemental oxygen and are not able to stop their oxygen for up to a few hours at a time, or who use oxygen because they have breathing when they are laying down",{"count":145,"type":20},28,[82],"This phase I trial finds out the best dose, possible benefits and\u002For side effects of papaverine when given together with chemoradiation intreating patients with stage II-III non-small cell lung cancer. Papaverine targets mitochondrial metabolism to decrease the cancer growth process. Giving papaverine with chemoradiation may work best to treat patients with non-small cell lung cancer.",[149,150,151,152,153,154,155,156,157],"Locally Advanced Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Unresectable Lung Non-Small Cell Carcinoma",{"date":64,"type":35},{"date":160,"type":35},"2021-12-06",{"date":162,"type":20},"2026-12-31",{"name":41,"class":42},2,{"id":166,"slug":4,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":164},"100491336","NCT05677802","Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer","Examining the Feasibility of Implementing a Biobehavioral Stress Reduction Program in Triple Negative Breast Cancer Patients","Inclusion Criteria:\n\n* Age \\>=18 years\n* Untreated newly diagnosed triple negative breast cancer\n* Stages I-III\n\nExclusion Criteria:\n\n* Prisoners\n* Male\n* Identifying as American Indian, Alaska Native, Asian, Native Hawaiian or Other Pacific Islander\n* Individuals not able to speak and understand English\n* Known personal history of ductal carcinoma in situ (DCIS) or invasive breast cancer\n* Stage IV breast cancer",{"count":172,"type":20},40,[23],"This clinical trial aims to see if patients with triple negative breast cancer can complete a biobehavioral stress reduction program that also addresses health related social needs (e.g., utilities, transportation, etc.). The stress reduction program is over ten weeks and includes stress reduction (e.g., progressive muscle relaxation), coping, problem solving, communication, and social support. Health related social needs will be evaluated at the beginning of the study, and referrals will be made to social work to help address those needs. The study will examine stress as reported by the patients and also use biological markers.",[27,28,29,176,177,178],"HER2-Negative Breast Carcinoma","Hormone Receptor-Negative Breast Carcinoma","Triple-Negative Breast Carcinoma","2026-06-24",{"date":181,"type":35},"2026-06-29",{"date":183,"type":35},"2022-12-14",{"date":185,"type":20},"2027-06-30",{"name":41,"class":42},{"id":188,"slug":4,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":78,"sex":49,"minAge":124,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":205,"locationsCount":43},"100637303","NCT07585006","Comparative Evaluation of Nicotine Analogs","CENA","Inclusion Criteria:\n\n* Aged 21 years or older\n* Current adult EC user for at least the past 3 months (confirmed by cotinine testing strip)\n* Willing and able to provide informed consent\n* Willing to abstain from using any nicotine, tobacco, or marijuana products for 12 or more hours prior to the three lab visits\n* Able to read, write, and speak English\n\nExclusion Criteria:\n\n* Currently attempting to quit nicotine or tobacco products\n* Use of other tobacco or nicotine products \\> 10 days in the past month\n* Have had a recent cardiac event or distress (defined as occurring within the previous 3 months)\n* Have had a recent serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, asthma, or lung cancer) (defined as occurring in the previous 30 days)\n* Currently pregnant, planning to become pregnant, or breastfeeding (verified with urine pregnancy test)",{"count":194,"type":20},70,[82],"This phase I trial compares electronic cigarette (EC) user preferences and smoking behaviors of nicotine analogs to nicotine to improve the understanding of nicotine analog addictiveness. Over the last ten years, EC use has become a major concern due to its increased use among adolescents and young adults. Though progress has been made in regulating nicotine containing products, some companies have shifted toward producing products containing nicotine analogs. ECs are battery-powered electronic devices designed to atomize a nicotine (the poisonous chemical found in tobacco)-containing liquid solution for inhalation in a manner that simulates smoking a tobacco cigarette. When nicotine enters the body, it causes an increased heart rate and use of oxygen by the heart, and a sense of well-being and relaxation. Nicotine analogs are compounds that are similar to nicotine in their chemical structure. Some nicotine analogs have been shown to have nicotine-like effects; however, more research is needed to prove they function similarly to nicotine and\u002For have similar effects. Comparing EC user preferences and smoking behaviors of nicotine analogs to nicotine may help improve the understanding of nicotine analog addictiveness.\n\nAdditionally, combustible cigarette smoking is well-known to have deleterious effects on cardiovascular health. High blood pressure is one of the major health consequences of cigarette smoking and can increase the risk of hypertension, heart attack, and stroke. Although ECs have been marketed as a less harmful alternative to cigarette smoking, clinical trials have shown that vaping ECs can also lead to acute increases in blood pressure and heart rate. Nicotine can alter vascular reactivity by promoting the release of vasoconstrictors and suppressing the production of vasodilators. No research has examined how the synthetic nicotine in ECs affects hemodynamics, vascular health, and endothelial function. Assessing acute cardiovascular responses to nicotine analogs is therefore critical to enhancing our understanding of the potential cardiovascular risks associated with vaping ECs containing synthetic nicotine.",[198,199],"Tobacco-Related Carcinoma","Addiction","2026-06-23",{"date":131,"type":35},{"date":203,"type":35},"2026-05-29",{"date":162,"type":20},{"name":41,"class":42},{"id":207,"slug":4,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":228,"locationsCount":43},"100609546","NCT07215988","Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a \"Filter\" Observational Study","Inclusion Criteria:\n\n* \\* MERKEL CELL CARCINOMA\n\n  * Signed informed consent\n  * Pathology report confirming Merkel at the time of screening\n  * Stage II, III or IV resectable (criteria based on Merkel Cell carcinoma TNM pathologic staging AJCC UICC 8th edition) or unresectable cancers amenable to surgery if a response is elicited with neoadjuvant therapy\n  * ≥ 18 years of age\n  * Genomics of the cancer attempted\n  * Description of planned surgical resection by surgeon\n  * Planned treatment with immunotherapy. Possible Beacon plan entitled OP NIVOLUMAB IPILIMUMAB NEUROENDOCRINE (PRL 8149)\n\n    * 2 cycles will be given prior to surgery (=12 weeks).\n\n      * MUCOSAL MELANOMA\n  * Signed informed consent\n  * Pathology report confirming mucosal melanoma at the time of screening\n  * Stage III or IV resectable (TNM pathologic staging AJCC UICC 8th edition) or unresectable cancers amenable to surgery if a response is elicited with neoadjuvant therapy\n  * ≥ 18 years of age\n  * Genomics of the cancer attempted\n  * Description of planned surgical resection by surgeon\n  * SOC (standard of care) treatment planned with immunotherapy Possible Beacon plan entitled OP NIVOLUMAB IPILIMUMAB -\\> NIVOLUMAB Q4 WEEK MAINTENANCE MELANOMA 4 cycles will be given prior to surgery (=12 weeks)\n\n    * BASAL CELL CARCINOMA\n  * Signed informed consent\n  * Pathology report confirming basal cell carcinoma with subtype at the time of screening\n  * Resectable tumor of any stage, or unresectable tumor that could be amenable to surgery if there is a good response.\n  * ≥ 18 years of age\n  * Genomics of the cancer attempted\n  * Description of planned surgical resection by surgeon\n  * SOC treatment planned with possible Beacon plan entitled OP SONIDEGIB BASAL CELL CARCINOMA 3 months will be given prior to surgery (= 12 weeks) (Vismodegib may be substituted if current national shortage of sonidegib persists)\n\n    * RARE CUTANEOUS CANCERS\n  * Signed informed consent\n  * Pathology report confirming squamous cell carcinoma at the time of screening\n  * Stage II, III, or IV resectable or (TNM pathologic staging AJCC UICC 8th edition) or unresectable cancers amenable to surgery if a response is elicited with neoadjuvant therapy\n  * ≥ 18 years of age\n  * Genomics of the cancer attempted\n  * Description of planned surgical resection by surgeon\n  * Planned SOC treatment with possible Beacon plan entitled OP WEEKLY CARBOPLATIN PACLITAXEL + PEMBROLIZUMAB Q3 WEEKS HEAD AND NECK\n\n    * 4 cycles will be given prior to surgery (= 12 weeks)\n\nExclusion Criteria:\n\n* \\* MERKEL CELL CARCINOMA\n\n  * Metastatic disease not amenable to complete resection\n  * Prior immunotherapy, chemotherapy, or radiation therapy for treatment of MCC within the past year\n  * Any clinically significant medical condition, which in the judgment of the attending physician would contraindicate immunotherapy\n  * Is pregnant or breast feeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of SOC treatment.\n\n    * MUCOSAL MELANOMA\n  * Metastatic disease not amenable to complete resection\n  * Prior immunotherapy, chemotherapy, or radiation therapy for treatment of this mucosal melanoma within the past year\n  * Any clinically significant medical condition, which in the judgment of the attending physician would contraindicate immunotherapy\n  * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of SOC treatment.\n\n    * BASAL CELL CARCINOMA\n  * Metastatic disease not amenable to complete resection\n  * Prior immunotherapy, chemotherapy, or radiation therapy for treatment of this basal cell carcinoma within the past year\n  * Any clinically significant medical condition, which in the judgment of the attending physician would contraindicate immunotherapy\n  * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of SOC treatment.\n\n    * RARE CUTANEOUS CANCERS\n  * Metastatic disease not amenable to complete resection\n  * Prior immunotherapy, chemotherapy, or radiation therapy for treatment of this mucosal melanoma within the past year\n  * Any clinically significant medical condition, which in the judgment of the attending physician would contraindicate immunotherapy\n  * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of SOC treatment.",{"count":194,"type":20},"This study evaluates the time spent on obtaining insurance approval and drugs, means of insurance coverage, out-of-pocket costs for patients, and the surgical outcomes after neoadjuvant treatment is completed in skin cancer patients receiving \"off label\" and \"on label\" neoadjuvant treatment. \"Neoadjuvant therapy\" means cancer treatment given before surgery. However, in many instances, neoadjuvant therapy is used as an \"off-label\" approach for several types of skin cancers. \"Off-label\" means that the FDA has not yet approved its use for that type of cancer. Therefore, insurance approval of these \"off-label\" treatments could be delayed compared to label use, and \"off-label\" treatments may require several weeks of pre-authorization. There is evidence that the delayed start of cancer treatment can lead to poorer outcomes.",[214,215,216,217,218,219,220,221],"Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8","Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8","Locally Advanced Basal Cell Carcinoma","Locally Advanced Malignant Skin Neoplasm","Locally Advanced Merkel Cell Carcinoma","Locally Advanced Mucosal Melanoma","Locally Advanced Squamous Cell Carcinoma","2026-06-22",{"date":224,"type":35},"2026-06-25",{"date":226,"type":35},"2026-02-04",{"date":39,"type":20},{"name":41,"class":42},{"id":230,"slug":4,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":237,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":248,"locationsCount":43},"100609700","NCT07217990","Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer","NoCUT-BC","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged 18 years or older\n4. Early-stage breast cancer diagnosis (cT1-3 N0 or cT1-2 N1) and a Human Epidermal Receptor 2 (HER2)-positive or triple negative breast cancer (TNBC) tumor molecular subtype\n5. Planning to receive neoadjuvant chemotherapy (NAC) and radiation therapy (RT)\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Inmate or prisoner\n3. Treatment with an investigational drug or other intervention throughout their breast cancer treatment\n4. Patients with skin involvement and\u002For distant metastases",{"count":236,"type":20},84,[82,238],"PHASE2","This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.",[55,241,242],"HER2-positive Breast Cancer","Triple Negative Breast Cancer","2026-06-20",{"date":179,"type":35},{"date":246,"type":20},"2026-09-15",{"date":39,"type":20},{"name":41,"class":42},{"id":250,"slug":4,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":78,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":21,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":266,"leadSponsor":267,"locationsCount":43},"100609588","NCT07216534","Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants","Piloting a Virtual Reality-Based, Randomized Controlled Trial of Psychosocial Responses to Neighborhood Physical Disorder","Inclusion Criteria:\n\n* Adults 18+\n* Must currently live (4+ night\u002Fweek) at the residence being studied. Only one resident per household will be selected\n* Must understand and be able to read English\n* Must agree to have residence photographed\n* Must be able to wear a VR head mounted display\n* Must live in neighborhood that has been selected for study\n* Must be willing and able to attend an approximately 2 hour in-person visit on Ohio State University (OSU) campus\n\nExclusion Criteria:\n\n* Pregnant women\n* Visual or mobility impairment\n* Cannot have epilepsy or other condition that would inhibit them from being able to use a VR headset",{"count":256,"type":20},32,[23],"This clinical trial compares virtual reality viewing of an unaltered streetscape versus a digitally manipulated opposite streetscape to assess the psychosocial response in participants. Visible measures of neighborhood factors might be associated with health outcomes and risk factors of those outcomes. Short-term exposure to virtual reality environments representing very high or very low levels of neighborhood physical disorder - presence or absence of garbage\u002Flitter, presence or absence of graffiti, presence or absence of an abandoned building, presence or absence of large dumpsters, poor or very well-kept building conditions, poor or very well-kept yard conditions, poor or very well-kept road verge conditions may be a safe and effective way to assess psychosocial response in participants.",[260,261,262],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm","Psychiatric Disorder","2026-06-17",{"date":222,"type":35},{"date":37,"type":20},{"date":162,"type":20},{"name":41,"class":42},{"id":269,"slug":4,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":43},"100604077","NCT07144826","Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy","A Randomized, Double-Blind, Placebo Controlled, Study to Investigate Efficacy of a Probiotic Intervention on the Gut and Vaginal Microbiome of Ovarian Cancer Patients Undergoing Treatment With Platinum Chemotherapy","Inclusion Criteria:\n\n* Ability to understand and willingness to sign a written consent form. In patients who do not speak English, ability to have informed consent form translated in their native language and have their native language translator present for consenting process\n* Age \\> 18 years old\n* Patient with advanced (stage II, III or IV) or recurrent ovarian cancer who will receive platinum-based chemotherapy as standard of care (cisplatin, carboplatin containing regimens)\n* Agreeable to participate in all research activities defined in the study\n* Agreeable to not take any other probiotic and\u002For prebiotic supplements outside of study intervention during the study\n* Agreeable to not make significant changes to their diet throughout the course of the study\n* Patients with ileostomy, colostomy are permitted to participate\n\nExclusion Criteria:\n\n* Borderline ovarian tumors\n* Prior allergy or food intolerance to any probiotic product\n* History of chronic inflammation or active structural abnormality of the digestive tract (e.g., inflammatory bowel disease requiring medications, active duodenal or gastric ulcer, complete large or small bowel intestinal obstruction, active fistula)\n* Patients who do not meet laboratory parameters for platinum-based chemotherapy, including absolute neutrophil count (ANC) \\\u003C 1500\n* Known hypersensitivity to any component of study product (Akkermansia muciniphila, Anaerobutyricum hallii, Clostridium beijerinckii, Clostridium butyricum and Bifidobacterium infantis, chicory inulin, magnesium stearate, grape food color, and silica)\n* Known hypersensitivity to \\> 4 first-line antimicrobial therapies against Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Anaerobutyricum hallii: penicillin, piperacillin, tetracycline, amoxicillin, ampicillin\n* Known hypersensitivity to \\> 4 first-line antimicrobial therapies against Bifidobacterium infantis Bi-26\\^Trademark (TM): gentamicin, kanamycin, streptomycin, tetracycline, erythromycin, clindamycin, ampicillin, vancomycin",{"count":275,"type":20},161,[277],"EARLY_PHASE1","This clinical trial evaluates the effects a probiotic intervention has on the gut and vaginal microbiome in patients undergoing chemotherapy for ovarian cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent). Gut health is also known as the gut microbiome. The microbiome includes all of the bacteria and organisms naturally found in the digestive tract. Probiotics are dietary supplements containing live microorganisms that may help keep the gastrointestinal tract healthy. A probiotic intervention during platinum chemotherapy in ovarian cancer patients may impact the gut and vaginal microbiota, quality of life, symptoms, and oncologic outcomes.",[280,281,282,283,284],"Advanced Ovarian Carcinoma","Recurrent Ovarian Carcinoma","Stage II Ovarian Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","2026-06-16",{"date":287,"type":35},"2026-06-18",{"date":289,"type":35},"2026-03-06",{"date":291,"type":20},"2027-07-09",{"name":41,"class":42},{"id":294,"slug":4,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":21,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":315,"locationsCount":43},"100301098","NCT03199651","Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer","Beating Lung Cancer in Ohio (BLCIO) Protocol","BLCIO","Inclusion Criteria:\n\n* AIM 1-3\n* Pathologically confirmed stage IV NSCLC (with any Eastern Cooperative Oncology Group \\[ECOG\\] performance status, and any NSCLC - adenocarcinoma, squamous cell, etc.) with available imaging OR patients who do not yet have their staging completed, but in the judgment of the physician are likely to be stage IV;\n\n  * Patients may be enrolled if the recruiter cannot reach the patient by the first office visit, preferably prior to starting therapy and no later than one month after starting therapy; (NCCN guidelines allow for a switch to targeted therapy from chemotherapy if testing comes back positive after starting chemotherapy)\n* English speaking; and\n* Willing to provide access to medical records, insurance and billing data, biospecimens and respond to questionnaires, typically by phone, but possibly to include online or in-person surveys\n* AIM 3 ONLY\n* Patients must be current smokers who smoke at least one cigarette most days per week, or recent quitters who smoked at least one cigarette most days per week (\\\u003C 3 months); and\n* Household members must be current smokers, defined as smoking at least one cigarette most days per week\n* Hearing and vision impairments that would prevent ability to complete consent, interviews, or sample collection\n\nExclusion Criteria:\n\n* Being treated with definitive chemoradiotherapy or surgery\n* Receiving treatment for advanced lung cancer for over one month before enrollment; OR",{"count":301,"type":20},3584,[23],"This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.",[305,306,307,308,309],"Cigarette Smoker","Current Smoker","Lung Adenocarcinoma","Squamous Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer","2026-06-15",{"date":263,"type":35},{"date":313,"type":35},"2017-07-17",{"date":136,"type":20},{"name":41,"class":42},{"id":317,"slug":4,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":49,"minAge":124,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":43},"100627967","NCT07455513","A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer","A Pilot\u002FFeasibility Study of the Buckeye Quit Stick: A Novel Resource for Successful Tobacco Cessation","Inclusion Criteria:\n\n* \\>= 21 years old\n* Speak and understand English\n* Established patient of the OSU thoracic clinics\n* Diagnosed with a thoracic malignancy or has a clinically suspected thoracic malignancy as documented by treating provider\n* Willing and able to participate in the study protocol (e.g., complete the survey and related study documents and provide informed consent)\n* Current self-reported smoker\n* Willingness to change = score of above 1 on the Stages of Change measure\n\nExclusion Criteria:\n\n* \\\u003C 21 years old (Ohio is a tobacco 21 state.)\n* Patient outside of the OSU clinics (This intervention targets patients who may benefit the most from cessation.)\n* Unwilling or unable to provide consent or complete study components\n* Prisoners will be excluded from participation",{"count":323,"type":20},30,[23],"This clinical trial evaluates the feasibility of a novel tobacco cessation resource called a Buckeye Quit Stick among smokers with a diagnosed or suspected thoracic cancer. Tobacco use is the single most preventable cause of disease, disability, and death in the United States. While the benefits of quitting smoking are numerous, rates of persistent smoking after cancer diagnosis remain high. Research has found that patients who quit smoking but subsequently relapse frequently report the hand\u002Foral habit as a barrier to sustained smoking cessation. The Buckeye Quit Stick is an innovative cessation aid designed to directly address patients' hand\u002Foral habit by substituting the cessation aid for cigarettes without integrating pharmacologic intervention, which is typically managed by their medical provider and may require direct supervision due to the patient's health status. The Buckeye Quit Stick is designed to satisfy the repeated hand\u002Foral pattern or ritual, thereby avoiding the physical loss of holding a cigarette in the hand or mouth and the action of smoking. It may also help occupy fidgeting hands and potentially reduce stress and cravings. This novel cessation resource may address key factors that influence smoking abstinence and improve patients' health outcomes.",[130,327],"Malignant Thoracic Neoplasm","2026-06-12",{"date":310,"type":35},{"date":331,"type":35},"2026-02-25",{"date":333,"type":20},"2027-03-31",{"name":41,"class":42},{"id":336,"slug":4,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":21,"phases":343,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":353,"locationsCount":43},"100340390","NCT03711890","Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer","Imaging and Detection of Micrometer Sized Early Stage Pancreatic Cancer by Using Endoscopic Ultra-High Resolution Optical Coherence Tomography (OCT) Using Resected Pancreatic Specimen, a Pilot Study","Inclusion Criteria:\n\n* Immediate surgery cohort: Adult patients with pancreatic cancer or IPMN\n* Immediate surgery cohort: Informed consent will be obtained\n* Adult patients undergoing pancreatic resection for a presumed IPMN\n\nExclusion Criteria:\n\n* Pregnant",{"count":342,"type":20},75,[23],"This trial studies how well ultra-high resolution optical coherence tomography works in detecting micrometer sized early stage pancreatic cancer in participants with pancreatic cancer. Ultra-high resolution optical coherence tomography may help to accurately identify pancreatic cancer in resected pancreatic specimens.",[346,347],"Pancreatic Carcinoma","Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type","2026-06-11",{"date":310,"type":35},{"date":351,"type":35},"2019-03-26",{"date":246,"type":20},{"name":41,"class":42},{"id":355,"slug":4,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":43},"100452975","NCT05178498","Impact of Dietary Inflammatory Potential on Breast Cancer Risk","Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Established in the high risk clinic at OSUCCC- James (includes patients with family history of breast cancer \\[BC\\], known genetic predisposition, personal history of known atypia\u002Fbreast lobular carcinoma in situ \\[LCIS\\], or prior chest wall radiation)\n* Patients at high risk for BC established in the surgical oncology clinic at Stefanie Spielman Comprehensive Breast Center (SSCBC), with one of the following diagnoses: Atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), sclerosing adenosis (SA), or radial scars (RS)\n* Able to read and understand English\n* Able to provide informed consent\n* Must consent to continued follow-up of medical records during the study period\n\nExclusion Criteria:\n\n* Prisoners\n* Not able to speak and understand English\n* Known personal history of ductal carcinoma in situ (DCIS) or Invasive BC",{"count":361,"type":20},960,"This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve prevention strategies, and provide timely intervention for early therapeutic management as needed.",[364,365,366,367,368],"Breast Atypical Ductal Hyperplasia","Breast Atypical Lobular Hyperplasia","Breast Carcinoma","Breast Lobular Carcinoma In Situ","Breast Sclerosing Adenosis","2026-06-10",{"date":328,"type":35},{"date":372,"type":35},"2023-10-25",{"date":374,"type":20},"2035-12-31",{"name":41,"class":42},{"id":377,"slug":4,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":78,"sex":49,"minAge":4,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":21,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":394,"locationsCount":43},"100540271","NCT06314672","Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial","The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) Project","Inclusion Criteria:\n\n* Phase I: 9 counties in the OSUCCC catchment area\n* Phase II: Patients, providers, and hospital systems\u002Freferral centers that directly addresses challenges identified in Phase I\n* Phase II: The project will involve the OSUCCC, the OSU James Cancer Network sites and the Columbus and Dayton NCORP sites",{"count":383,"type":20},208,[23],"This clinical trial tests the impact of the The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) project on clinical trial referrals and enrollment in racial\u002Fethnic minorities. Progress in cancer prevention, detection and treatment can only be made by identifying and validating new and improved methods, compounds and modalities in clinical trials. Unfortunately, participation in clinical trials is not equal across all racial and ethnic groups, limiting progress against cancer in all population groups and further widening the disparity gap. To change this picture, concerted effort needs to be directed both at the communities at risk for being left out of trials and the systems that cause the disparities at all levels involved in accrual to clinical trials. The CUSP2CT project may have the potential to increase referral and accrual of racial\u002Fethnic minorities to prevention\u002Fcontrol and treatment trials.",[387,261],"Hematopoietic and Lymphoid System Neoplasm","2026-06-05",{"date":390,"type":35},"2026-06-09",{"date":392,"type":35},"2023-08-22",{"date":136,"type":20},{"name":41,"class":42},{"id":396,"slug":4,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":78,"sex":49,"minAge":124,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":21,"phases":402,"briefSummary":403,"conditions":404,"keywords":407,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":412,"leadSponsor":414,"locationsCount":43},"100636358","NCT07564648","Impact of Novel vs. Usual Brand Menthol Cigarettes on Abuse Liability","Inclusion Criteria:\n\n* Aged 21 years or older\n* Currently smoke cigarettes daily (≥ 5 cigarettes\u002Fday) for at least the past 6 months, and their usual brand is menthol cigarettes\n* Willing to provide informed consent\n* Willing to abstain from all nicotine, tobacco, and smoked cannabis products for approximately 12 hours prior to each study visit\n* Own and regularly use a functional smartphone compatible with study procedures (e.g., completing daily assessments)\n* Willing to complete two weeks of daily assessments involving use of their usual brand menthol cigarettes and the study product\n* Able to read, speak, and understand English\n\nExclusion Criteria:\n\n* Current diagnosis of any significant lung diseases (e.g., asthma, chronic obstructive pulmonary disease, cystic fibrosis)\n* History of a cardiac event or episode of cardiac distress (e.g., heart attack, hospitalization for chest pain) within the past 3 months\n* Currently pregnant, planning to become pregnant during the study period, or currently breastfeeding\n* Self-reported use of any non-cigarette nicotine or tobacco product (e.g., e-cigarettes, cigars, oral nicotine products) or cannabis on more than 10 days in the past 30 days\n* Self-reported current participation in a smoking cessation program or intention to quit smoking in the next 3 months\n* Self-reported difficulty with blood draws",{"count":401,"type":20},48,[23],"This randomized, double-blind, crossover human laboratory study compares the abuse liability of cigarettes containing menthol and non-menthol cigarette variants, using the participant's usual brand menthol cigarette as a within-subject reference. Participants complete standardized laboratory smoking sessions, behavioral economic tasks, and a naturalistic observational period. The study examines differences in nicotine delivery, smoking behavior, and subjective effects across cigarette types in laboratory and real-world contexts.",[405,406],"Cigarette Addiction","Tobacco Use Disorder",[405,408],"Cigarette","2026-06-03",{"date":388,"type":35},{"date":222,"type":20},{"date":413,"type":20},"2029-09-30",{"name":41,"class":42},{"id":416,"slug":4,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":78,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":21,"phases":423,"briefSummary":424,"conditions":425,"keywords":435,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":441,"leadSponsor":442,"locationsCount":43},"100640818","NCT07606287","Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital","Implementation of the American College of Surgeons Geriatric Surgery Verification Program at the James Cancer Hospital","Inclusion Criteria:\n\n1. Patient records for adults aged 65 years or older\n2. Patient records with a surgical encounter or preoperative evaluation within participating James Cancer Hospital surgical oncology services during the rollout period\n3. Patient records with data available in institutional electronic health record or institutional data systems\n4. Clinical staff age 18 years or older who are employed or credentialed at The Ohio State University Wexner Medical Center and work within clinical areas affected by ACS Geriatric Surgery Verification implementation\n\nExclusion Criteria:\n\n1. Patient records for encounters occurring only at outside institutions or non-James hospitals within the enterprise\n2. Patient records missing all primary outcome fields after data quality checks\n3. Clinical staff who are trainees, including medical students, physician assistant students, nursing students, resident physicians, or fellows\n4. Clinical staff whose employment, visa, or institutional status would make participation sensitive under institutional policy, if applicable",{"count":422,"type":20},4000,[23],"This study examines how the American College of Surgeons Geriatric Surgery Verification Program, also called the ACS GSV Program, is implemented at the James Cancer Hospital. The program is designed to improve surgical care for adults age 65 and older by helping care teams identify and address age-related needs before, during, and after surgery.\n\nOlder adults with cancer may have concerns related to physical function, memory or thinking, medications, social support, and goals of care. If these needs are not recognized, patients may be at higher risk for complications, longer hospital stays, readmission, or discharge to a facility instead of home.\n\nThe ACS GSV Program includes standards for geriatric surgery leadership, goals-of-care discussions, screening for age-related vulnerabilities, care plans for identified needs, age-friendly perioperative care, and regular review of surgical outcomes. This study will evaluate how well these standards are adopted across surgical oncology services and whether implementation is associated with better outcomes, such as shorter hospital stays, fewer complications, fewer readmissions, and improved discharge outcomes.\n\nThe results may help improve surgical care workflows for older adults undergoing cancer surgery.",[366,426,427,428,429,430,261,327,431,432,433,434],"Malignant Digestive System Neoplasm","Malignant Female Reproductive System Neoplasm","Malignant Genitourinary System Neoplasm","Malignant Head and Neck Neoplasm","Malignant Nervous System Neoplasm","Skin Neoplasm","Soft Tissue Neoplasm","Central Nervous System Neoplasm","Endocrine Gland Neoplasms",[436,437],"geriatric surgery verification","oncogeriatrics","2026-05-27",{"date":203,"type":35},{"date":310,"type":20},{"date":39,"type":20},{"name":41,"class":42},{"id":444,"slug":4,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":21,"phases":450,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":459,"locationsCount":43},"100640601","NCT07619391","MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer","A Mobile App for Tracking Time Burden of Pancreatic Cancer Treatment: A Single-Arm Feasibility Study","Inclusion Criteria:\n\n* Adults ≥ 18 years old\n* Diagnosed with pancreatic adenocarcinoma undergoing active treatment or planning to start active treatment within the next 30 days\n* English speaking\n* Access to a smartphone (Android or iOS)\n\nExclusion Criteria:\n\n* Prisoners\n* Patients undergoing cancer surveillance",{"count":323,"type":20},[23],"This clinical trial tests the feasibility of using the MyCap mobile application (app) for tracking time burden from treatment for patients with pancreatic cancer. Pancreatic cancer is best treated with many care teams, such as medical oncology and surgery, requiring patients to dedicate significant time coordinating appointments among different doctors. This time commitment is referred to as time toxicity, defined as the time spent undergoing cancer-related medical care, such as emergency visits, ambulatory care, lab and infusion visits, hospitalizations, and the commuting and waiting times associated with each. At present, time toxicity is still understudied within the medical literature, with no gold standard established for the method of measurement. The MyCap mobile app may be a feasible way to track the time burden from treatment for patients with pancreatic cancer.",[453],"Pancreatic Adenocarcinoma",{"date":455,"type":35},"2026-06-02",{"date":457,"type":35},"2026-03-10",{"date":39,"type":20},{"name":41,"class":42},{"id":461,"slug":4,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":21,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":43},"100637717","NCT07619417","Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms","Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation of Pancreatic Neoplasms - A Safety and Feasibility Trial","Inclusion Criteria:\n\n* Age \\> 18 years\n* A diagnosis of a pancreatic neoplasm confirmed by EUS-fine needle aspiration (FNA) - (a) pancreatic cystic lesion such as intraductal papillary-mucinous neoplasm (IPMN), (b) World Health Organization (WHO) grade I neuroendocrine tumor\n* Lesion size estimation by computed tomography (CT) or magnetic resonance imaging (MRI)\u002Fmagnetic resonance cholangiopancreatography (MRCP) or EUS: (a) pancreatic cystic lesion such as IPMN - at least 2 cm in diameter. (b) WHO grade I neuroendocrine tumor - at least 1 cm in diameter\n* The patient is not a surgical candidate. Common clinical scenarios include -\n\n  * Cirrhosis of the liver (common clinical scenario)\n  * Advanced (≥ 75 years) age (common clinical scenario)\n  * Morbid obesity\n  * Significant cardiorespiratory comorbidity\n  * Patient's choice (patient elects for non-surgical management)\n  * Other significant comorbid conditions that impose prohibitive surgical risks\n  * The patient prefers non-surgical management after consultation with hepato-pancreato-biliary (HPB) surgery\n* For pancreatic neuroendocrine tumor (PNET) and all pancreatic cystic lesions (PCLs): Estimated life expectancy of at least 1 year\n* Capable of giving written informed consent or has a legally authorized representative (LAR) to consent for them\n* Women of childbearing potential must have a negative pregnancy test (serum\u002Furine) on the day of treatment. Pregnancy testing is the routine standard of care practice in the endoscopy laboratory for all patients undergoing endoscopy and sedation for endoscopy\n* The patient is not a surgical candidate and has had prior attempts at ablation of the PCN by EUS-RFA (Ohio State University \\[OSU\\] Institutional Review Board \\[IRB\\] protocol: 2023C0004)\n\nExclusion Criteria:\n\n* Any evidence of severe or uncontrolled systemic diseases, or laboratory findings that, in the investigator's opinion, make it unsafe for the patient to participate in the study study\n* Pregnancy or breast-feeding\n* Clinical frailty scale\n* Contraindication to general anesthesia after review by OSU Preoperative Assessment Clinic (OPAC)",{"count":467,"type":20},12,[23],"This clinical trial tests the safety and feasibility of endoscopic ultrasound-guided pulsed electric field ablation for the treatment of pancreatic neoplasms. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage. The approach for pancreatic neoplasm treatment has changed and the recognition of minimally invasive treatments is growing. One such minimally invasive treatment, known as endoscopic ultrasound-guided pulsed electric field ablation, offers an alternative to surgery for managing certain precancerous or high-risk pancreatic cysts. The Aliya Pulsed Electric Field system uses brief, strong bursts of electricity, delivered through a thin needle, to destroy targeted tissue, such as tumors, without using heat. These electric pulses damage only the cells inside the treatment zone, leaving the healthy tissues and important nearby structures unharmed. This makes the treatment safer and less likely to cause harm to sensitive areas around the tumor. Endoscopic ultrasound-guided pulsed electric field ablation may be safe and feasible for the treatment of pancreatic neoplasms.",[471,472],"Pancreatic Neoplasm","Pancreatic Neuroendocrine Tumor",{"date":455,"type":35},{"date":475,"type":20},"2026-08-01",{"date":39,"type":20},{"name":41,"class":42},{"id":479,"slug":4,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":21,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":43},"100633653","NCT07529483","Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms","Endoscopic Ultrasound-Guided Chemoablation of Pancreatic Cysts - An Efficacy Trial","ERASE-Chemo","Inclusion Criteria:\n\n* Age \\> 18 years\n* A diagnosis of a pancreatic cystic neoplasm (PCN) confirmed by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) including cyst fluid next-generation sequencing (NGS) and\u002For EUS-needle based confocal laser endomicroscopy (nCLE) and\u002For EUS-through the needle biopsy (TTNB)\n* The pancreatic cystic lesion (PCL) measures at least 1 cm in diameter on CT, MRI\u002FMRCP, or EUS\n* This cohort may include patients with PCNs previously treated with other ablative modalities include EUS-radiofrequency ablation (RFA) (NCT05961982, institutional review board \\[IRB\\]: 2023C0004) or EUS-pulsed electric field (PEF) (IRB 20251089) who have shown either no response or only a partial response to therapy\n* The patient is not a surgical candidate. Common clinical scenarios include-\n\n  * Cirrhosis of the liver (common clinical scenario)\n  * Advanced (≥ 75 years) age (common clinical scenario)\n  * Morbid obesity\n  * Significant cardiorespiratory comorbidity\n  * Patient's choice (patient elects for non-surgical management)\n  * Other significant comorbid conditions that impose prohibitive surgical risks\n* Estimated life expectancy of at least 1 year\n* Capable of giving written informed consent or has a legally authorized representative (LAR) to consent for them\n* Women of childbearing potential must have a negative pregnancy test (serum\u002Furine) on the day of treatment. Pregnancy testing is the routine standard of care practice in the endoscopy laboratory for all patients undergoing endoscopy and sedation for endoscopy\n\nExclusion Criteria:\n\n* Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it unsafe for the patient to participate in the study\n* Any psychiatric disorder making reliable informed consent impossible\n* Pregnancy or breast-feeding\n\n  * Pregnant patients will be excluded due to confounding variables\n* Contraindication to general anesthesia after review by Ohio State University (OSU) Preoperative Assessment Clinic (OPAC)\n* Non-English speaking individuals are excluded because study materials, consent forms, and validated patient-reported assessments are available only in English, and interpreter-mediated consent could compromise comprehension of procedural risks associated with an investigational intervention",{"count":486,"type":20},35,[238],"This phase II trial tests the effect of endoscopic ultrasound (EUS)-guided chemoablation in treating patients with pancreatic cysts. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage, and the five-year survival rate is currently less than 10%. Pancreatic cysts are a common precancerous lesion that may develop into pancreatic cancer. An EUS is a procedure in which an endoscope is inserted into the body. An endoscope is a thin, tube-like instrument that has a light and a lens for viewing. A probe at the end of the endoscope is used to bounce high-energy sound waves (ultrasound) off internal organs to make a picture (sonogram). EUS-guided chemoablation uses a fine needle inserted into the pancreatic cyst to deliver chemotherapy, such as gemcitabine and paclitaxel, directly into the cyst (\"intracystic\"). Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. An EUS-guided chemoablation, with gemcitabine and paclitaxel, may be an effective minimally invasive strategy to destroy abnormal or precancerous cells while reducing exposure to the rest of the body in patients with pancreatic cysts.",[490],"Pancreatic Cystic Neoplasm",{"date":203,"type":35},{"date":493,"type":35},"2026-05-12",{"date":39,"type":20},{"name":41,"class":42},{"id":497,"slug":4,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":21,"phases":503,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":43},"100638566","NCT07584239","Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery, ROAR-LCS Trial","LiveWellLung: A Prehabilitation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery (ROAR-LCS) With Biospecimen Collection","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosed with: potentially resectable non small cell lung cancer (NSCLC) stage (9th edition: IB-IIIB)\n* Intent to receive surgery following neoadjuvant systemic therapy from the Ohio State University Comprehensive Cancer Center (OSUCCC) Thoracic Oncology Clinic\n* Patients who are at least 6 weeks out of the surgery date are eligible to participate\n* Willingness to participate and adhere to the study intervention program\n* Ability to understand and willingness to sign an informed consent document\n\nExclusion Criteria:\n\n* Prisoners are excluded from participation\n* There is NO exclusion criteria pertaining to Eastern Cooperative Oncology Group (ECOG) performance status, laboratory values, or prior cancer diagnoses\n* Patients already enrolled on a therapeutic clinical trial will be excluded from this study as to not confound any exploratory outcomes associated with this trial and\u002For any clinical trials evaluating novel anti-cancer therapies unless granted permission by the local site principal investigator (PI)",{"count":323,"type":20},[23],"This clinical trial tests two different physical therapy and relaxation interventions, one in-person and at-home called Resiliency and Operative Success for Adults Receiving Lung Cancer Surgery (ROAR-LCS) and one virtually called BeFitMe. These programs that take place before and after standard of care lung cancer surgery, called prehabilitation programs, promote resiliency and patient outcomes (operative success) for adults receiving lung cancer surgery. Lung cancers occur in the chest and often cause symptoms for patients. Poor physical performance and negative mood are two risk factors for a decline in functional status after surgery. Physical therapy and relaxation interventions (i.e. progressive muscle relaxation) are two such interventions that may improve physical and emotional recovery including a potential shortened hospital stay for patients receiving surgery for lung cancer. Starting these intervention programs early alongside cancer treatment can improve symptoms, improve functional status and quality of life, help with emotional needs of patients, improve recovery time, and may even prolong life. ROAR-LCS and BeFitMe may promote resiliency and operative success for adults receiving lung cancer surgery.",[506],"Resectable Lung Non-Small Cell Carcinoma","2026-05-21",{"date":509,"type":35},"2026-05-26",{"date":511,"type":20},"2026-07-15",{"date":162,"type":20},{"name":41,"class":42},{"id":515,"slug":4,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":78,"sex":49,"minAge":124,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":21,"phases":523,"briefSummary":525,"conditions":526,"keywords":527,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":536,"locationsCount":43},"100631687","NCT07503925","THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health","THRIVE Study: Informing Oral Nicotine Pouch Regulations to Promote Public Health","THRIVE","Inclusion Criteria:\n\n* Age 21 or older\n* Able to read and speak English\n* Willing to abstain from tobacco, nicotine, and marijuana for at least 12 hours prior to study visits\n* Exclusive use of ONPs (other product use \\\u003C10x\u002Fmo).\n* Exhaled CO reading \\\u003C10 ppm\n* Owns a smartphone and can receive SMS text messages with embedded survey links\n* Negative pregnancy test at V1 and V2 (if applicable)\n* Uses ≥1.5 cans of ONPs\u002Fweek\n* Daily use of ONPs for the past 3 months\n* At least half of ONPs used are 6mg nicotine concentration.\n\nExclusion Criteria:\n\n* Non-English speaker\n* Individuals currently pregnant, planning to become pregnant, or breastfeeding are excluded due to potential risks associated with nicotine exposure and study procedures (e.g., blood draws).\n* Individuals with unstable or significant psychiatric conditions are excluded to minimize risk and ensure reliable participation.\n* Individuals actively attempting to quit nicotine use are excluded to avoid ethical concerns and ensure that study participation does not interfere with cessation efforts\n* Non-nicotine users and regular tobacco users are excluded from the clinical trial component to ensure that participants have established use patterns appropriate for assessing ONP use behaviors.",{"count":522,"type":20},15,[524],"PHASE4","Although nicotine pouches have been gaining popularity over the last few years, little known about how nicotine pouch users actually use these products.\n\nThis study will be comprised of adults who use nicotine pouches. If eligible, participants will be asked to complete three study visits and participate in two switching periods where participants use study-provided nicotine pouches.",[198],[528,529,530,531],"Tobacco","Oral Nicotine Pouches","Particle Size","Tobacco Regulation",{"date":509,"type":35},{"date":534,"type":20},"2026-07-01",{"date":39,"type":20},{"name":41,"class":42},{"id":538,"slug":4,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":21,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":557,"locationsCount":43},"100638264","NCT07609030","A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma","Intervention to Enhance Cognitive Augmentation and Neuroplasticity (I-CAN)","Inclusion Criteria:\n\n* Patients \\>= 18 years of age\n* Diagnosed with relapsed\u002Frefractory multiple myeloma (MM) or B-cell non-Hodgkin lymphoma (B-NHL)\n* Expected to receive an Food and Drug administration (FDA)-approved CAR-T cellular treatment\n* English literacy\n\nExclusion Criteria:\n\n* Patients expected to live \\\u003C 6 months\n* Patients with major medical disorder known to affect cognition, such as stroke, encephalitis, traumatic brain injury, brain surgery\n* Confirmed Alzheimer disease or other dementia\n* Previous central nervous system (CNS) radiation\n* Active intrathecal therapy at time of enrollment",{"count":544,"type":20},90,[23],"This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \\[I-CAN\\]), delivered before and after treatment with chimeric antigen receptor T-cell therapy, works to improve cognitive and neurological outcomes in patients with multiple myeloma or B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Cancer treatment can have significant short and long-term side effects, including cognitive and neurological side effects such as impairments in attention, memory, language, and executive function. The I-CAN program is a form of cognitive training. Cognitive training is a therapeutic approach designed to improve and restore cognitive functioning, based on the brain's ability to reorganize and form new neural connections to accomplish tasks. I-CAN provides five core elements necessary for training the brain to create new neural connections including speed of processing, accuracy of processing, adaptivity, generalizability, and engagement. The I-CAN intervention, when delivered before and after therapy, may help reduce the cognitive side effects of treatment in patients with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.",[548,549,550,551],"Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Multiple Myeloma","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Multiple Myeloma","2026-05-19",{"date":438,"type":35},{"date":555,"type":35},"2026-04-28",{"date":39,"type":20},{"name":41,"class":42},""]